Multiple System Atrophy Treatment
Aug 12, 2025
Teva’s AJOVY Expanded by FDA as First Anti-CGRP Preventive for Pediatric Episodic Migraine; NRx Pharma’s NRX-100 Granted FDA Fast Track for Suicidal Ideation in Depression/Bipolar Depression; Boehringer Ingelheim’s HERNEXEOS Wins FDA Accelerated Approval for HER2-Mutant Advanced NSCLC; Genmab’s Phase III EPCORE FL-1 Meets Dual Endpoints in Relapsed/Refractory Follicular Lymphoma; Tiziana’s Phase II IND Cleared by FDA for Multiple System Atrophy
FDA Expands Teva’s AJOVY As First Anti-CGRP Preventive For Pediatric Episodic Migraine Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the FDA has approved AJOVY (fremanezumab-vfrm) for the preventive treatment of episodic migraine in children and adolescents aged 6–...
Read More...
Jan 27, 2025
The Future of Multiple System Atrophy Treatment: Pioneering Approaches Beyond Levodopa Reliance
Multiple system atrophy (MSA) is a rare and progressive neurodegenerative disorder that affects the autonomic nervous system, motor function, and balance. It manifests through a combination of parkinsonism, autonomic dysfunction, and cerebellar ataxia, making it distinct from Parkinson’s disease despite overlapping...
Read More...
Jun 19, 2023
Evolving Landscape of Multiple System Atrophy Treatment: Recent Developments and Future Directions
Multiple system atrophy (MSA) is a rare disease that affects between 15,000 and 50,000 Americans, encompassing men and women of all races. Multiple system atrophy has an unknown cause. The great majority of cases are sporadic, meaning they happen at random. The peak onset of multiple system atrophy occurs between t...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
